# CRIM1

## Overview
CRIM1 is a gene that encodes the cysteine-rich transmembrane BMP regulator 1, a type I transmembrane protein involved in various cellular processes. This protein is characterized by its cysteine-rich domains, which facilitate interactions with bone morphogenetic proteins (BMPs) such as BMP4 and BMP7, modulating their activity and influencing cellular growth and differentiation (Wilkinson2003CRIM1). CRIM1 plays a critical role in stabilizing cell-cell junctions through its interactions with ß-catenin and cadherins, which are essential for neural morphogenesis and other developmental processes (Ponferrada2012CRIM1). The gene's clinical significance is underscored by its association with various conditions, including colobomatous macrophthalmia with microcornea syndrome and pterygium development, highlighting its importance in ocular and developmental biology (Beleggia2015CRIM1; Maurizi2019A).

## Structure
The CRIM1 protein is a type I transmembrane protein characterized by a C-terminal transmembrane domain and a large N-terminal cysteine-rich domain that localizes in the extracellular space (Wilkinson2003CRIM1). It contains six von Willebrand-like cysteine-rich repeats (CRRs) and an N-terminal insulin-like growth factor binding protein-like motif (Wilkinson2003CRIM1). These CRRs are crucial for its function, particularly in binding to bone morphogenetic proteins (BMPs) such as BMP4 and BMP7, which occurs intracellularly within the Golgi compartment (Wilkinson2003CRIM1).

CRIM1 is glycosylated, as evidenced by a molecular mass shift upon treatment with N-glycosidase, indicating the presence of N-glycosylation sites in its extracellular domain (Wilkinson2003CRIM1). The protein can be cleaved to release a soluble ectodomain, suggesting a mechanism for its secretion (Wilkinson2003CRIM1). The CRR domains have a conserved consensus sequence based on ten cysteines, a feature shared with other proteins interacting with the TGFβ superfamily (Wilkinson2003CRIM1). While specific details on the tertiary or quaternary structure are not provided, the CRR domains' cooperative binding to BMPs suggests a complex structural role in modulating BMP activity (Wilkinson2003CRIM1).

## Function
CRIM1 is a type I transmembrane protein that plays a significant role in stabilizing cell-cell junctions, particularly through its interaction with ß-catenin and cadherins. This interaction is crucial for the proper localization of ß-catenin to junctional complexes, which is essential for maintaining the integrity of these cell-cell junctions (Ponferrada2012CRIM1). CRIM1 forms complexes with ß-catenin and N-cadherin via its cytoplasmic domain, which is necessary for the stabilization of cadherin junctions. This function is vital for neural morphogenesis and potentially other cellular processes in healthy human cells (Ponferrada2012CRIM1).

CRIM1 also interacts with bone morphogenetic proteins (BMPs), particularly BMP4 and BMP7, acting as an antagonist. It modulates BMP activity by affecting their processing and delivery to the cell surface, which influences cellular processes such as growth and differentiation (Wilkinson2003CRIM1). CRIM1's interaction with BMPs occurs within the Golgi compartment, reducing the production and secretion of mature BMPs, thereby modulating their signaling properties (Wilkinson2003CRIM1). This regulatory function is crucial for various developmental processes, including the development of the central nervous system and renal organogenesis (Nyström2009CRIM1).

## Clinical Significance
Mutations and alterations in the CRIM1 gene are associated with several diseases and conditions. CRIM1 haploinsufficiency is linked to colobomatous macrophthalmia with microcornea syndrome (MACOM), an autosomal dominant eye malformation characterized by microcornea, coloboma, and severe myopia. This condition is caused by a heterozygous deletion in the CRIM1 gene, affecting exons 14-17, which disrupts the gene's role in eye development (Beleggia2015CRIM1).

In mice, a Crim1 C140S mutation, resulting from a cysteine-to-serine substitution, leads to phenotypes such as dwarfism, microphthalmia, and syndactyly. This mutation affects the stability and function of the CRIM1 protein by disrupting an intramolecular disulfide bond, highlighting the importance of cysteine 140 in the protein's physiological functions (Furuichi2019Crim1C140S).

CRIM1 is also implicated in pterygium development, a condition characterized by fibrovascular growth on the ocular surface. A specific variant, H412P, was identified in a Northern Irish family, suggesting a genetic component to the disease. CRIM1 overexpression in response to UV exposure affects cell proliferation and apoptosis, indicating its role in protecting against pterygium formation (Maurizi2019A).

## Interactions
CRIM1 is known to participate in several protein interactions that are crucial for its function in cellular processes. It forms complexes with ß-catenin and cadherins, particularly N-cadherin, through its cytoplasmic domain. This interaction is essential for stabilizing cell-cell junctions and is critical for neural morphogenesis. The presence of the cytoplasmic domain is necessary for these interactions, as demonstrated by immunoprecipitation experiments (Ponferrada2012CRIM1). CRIM1 can also self-associate, forming complexes with multiple CRIM1 molecules, as shown by co-immunoprecipitation experiments in HEK293 cells. The N-terminal region containing the IGFBP-like domain is sufficient for CRIM1 self-association (Ponferrada2012CRIM1).

CRIM1 interacts with bone morphogenetic proteins (BMPs), specifically BMP4 and BMP7, through its cysteine-rich repeat (CRR) domains. This interaction occurs intracellularly and affects the processing and delivery of BMPs to the cell surface. CRIM1 can bind to the precursor form of BMP4 and retains BMP7 on the cell surface, suggesting a role in modulating BMP activity and localization (Wilkinson2003CRIM1). These interactions highlight CRIM1's role in regulating BMP signaling pathways, which are crucial for various developmental processes.


## References


[1. (Ponferrada2012CRIM1) Virgilio G. Ponferrada, Jieqing Fan, Jefferson E. Vallance, Shengyong Hu, Aygun Mamedova, Scott A. Rankin, Matthew Kofron, Aaron M. Zorn, Rashmi S. Hegde, and Richard A. Lang. Crim1 complexes with ß-catenin and cadherins, stabilizes cell-cell junctions and is critical for neural morphogenesis. PLoS ONE, 7(3):e32635, March 2012. URL: http://dx.doi.org/10.1371/journal.pone.0032635, doi:10.1371/journal.pone.0032635. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0032635)

[2. (Wilkinson2003CRIM1) Lorine Wilkinson, Gabriel Kolle, Daying Wen, Michael Piper, Julie Scott, and Melissa Little. Crim1 regulates the rate of processing and delivery of bone morphogenetic proteins to the cell surface. Journal of Biological Chemistry, 278(36):34181–34188, September 2003. URL: http://dx.doi.org/10.1074/jbc.M301247200, doi:10.1074/jbc.m301247200. This article has 129 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M301247200)

[3. (Maurizi2019A) Eleonora Maurizi, Davide Schiroli, Sarah D. Atkinson, Laura Mairs, David G. Courtney, Barry O’Hagan, Victoria E. McGilligan, Alastair T. Pagnamenta, Jenny C. Taylor, Jesus J.D. Vasquez, Daniel E. Illanes-Velarde, Dave Goldsmith, Pieter Gouws, Jonathan E. Moore, M. Andrew Nesbit, and C.B. Tara Moore. A novel role for crim1 in the corneal response to uv and pterygium development. Experimental Eye Research, 179:75–92, February 2019. URL: http://dx.doi.org/10.1016/j.exer.2018.10.012, doi:10.1016/j.exer.2018.10.012. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.exer.2018.10.012)

[4. (Nyström2009CRIM1) Jenny Nyström, Kjell Hultenby, Sara Ek, Jonas Sjölund, Håkan Axelson, Karin Jirström, Moin A. Saleem, Kristina Nilsson, and Martin E. Johansson. Crim1 is localized to the podocyte filtration slit diaphragm of the adult human kidney. Nephrology Dialysis Transplantation, 24(7):2038–2044, January 2009. URL: http://dx.doi.org/10.1093/ndt/gfn743, doi:10.1093/ndt/gfn743. This article has 12 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/ndt/gfn743)

[5. (Beleggia2015CRIM1) F. Beleggia, Y. Li, J. Fan, N. H. Elcio lu, E. Toker, T. Wieland, I. H. Maumenee, N. A. Akarsu, T. Meitinger, T. M. Strom, R. Lang, and B. Wollnik. Crim1 haploinsufficiency causes defects in eye development in human and mouse. Human Molecular Genetics, 24(8):2267–2273, January 2015. URL: http://dx.doi.org/10.1093/hmg/ddu744, doi:10.1093/hmg/ddu744. This article has 26 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddu744)

[6. (Furuichi2019Crim1C140S) Tatsuya Furuichi, Manami Tsukamoto, Masaki Saito, Yuriko Sato, Nobuyasu Oiji, Kazuhiro Yagami, Ryutaro Fukumura, Yoichi Gondo, Long Guo, Shiro Ikegawa, Yu Yamamori, and Kentaro Tomii. Crim1c140s mutant mice reveal the importance of cysteine 140 in the internal region 1 of crim1 for its physiological functions. Mammalian Genome, 30(11–12):329–338, November 2019. URL: http://dx.doi.org/10.1007/s00335-019-09822-3, doi:10.1007/s00335-019-09822-3. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00335-019-09822-3)